Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)

This publication has 25 references indexed in Scilit:

• Response to Letter Regarding Article, “Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time”
  Circulation, 2008
• Statistical Evaluation of Prognostic versus Diagnostic Models: Beyond the ROC Curve
  Clinical Chemistry, 2008
• Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
  Statistics in Medicine, 2007
• Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data
  Clinical Chemistry, 2006
• The Seattle Heart Failure Model
  Circulation, 2006
• Predictors of mortality and morbidity in patients with chronic heart failure
  European Heart Journal, 2005
• Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both
  The American Journal of Cardiology, 2005
• A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
  New England Journal of Medicine, 2001
• The Amino-Terminal Portion of Pro-Brain Natriuretic Peptide (Pro-BNP) Circulates in Human Plasma
  Biochemical and Biophysical Research Communications, 1995
• A new natriuretic peptide in porcine brain
  Nature, 1988